New CRISPR approach may open path to hepatitis E treatment by blocking viral RNA

Researchers at the Ruhr University Bochum have developed a novel antiviral concept: Using the CRISPR/Cas13 system, they were able to specifically suppress the replication of the hepatitis E virus in human cells. Hepatitis E is a common cause of acute liver inflammation worldwide, yet effective specific therapies are still lacking. The team has now demonstrated that the virus can be targeted using an RNA-directed CRISPR system. The results, published on May 4, 2026, in the journal JHEP Reports, open new perspectives for the development of antiviral strategies.